Приказ основних података о документу
The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis
dc.creator | Donia, Marco | |
dc.creator | Mijatović, Sanja | |
dc.creator | Maksimović-Ivanić, Danijela | |
dc.creator | Miljković, Đorđe | |
dc.creator | Mangano, Katia | |
dc.creator | Tumino, Salvatore | |
dc.creator | Biondi, Antonio | |
dc.creator | Basile, Francesco | |
dc.creator | Al-Abed, Yousef | |
dc.creator | Stošić-Grujičić, Stanislava | |
dc.creator | Nicoletti, Ferdinando | |
dc.date.accessioned | 2017-11-23T11:12:34Z | |
dc.date.available | 2015-11-17T10:26:51Z | |
dc.date.issued | 2009 | sr |
dc.identifier.issn | 0014-2999 | sr |
dc.identifier.other | Rad_konverzija_3433 | sr |
dc.identifier.uri | https://radar.ibiss.bg.ac.rs/handle/123456789/1438 | |
dc.description.abstract | We investigated the effects of the recently synthetized NO donating agent GIT-27NO on the growth of human androgen independent and androgen dependent PC3 and LnCap cells xenografted in nude mice. We also tested the effects of GIT-27NO in the preclinical model of cell-mediated immunoinflammatory hepatitis that can be induced in mice by Concanavalin A (ConA) and that has been shown to benefit from the treatment with NO donating agents such as NO-aspirin. In agreement with in vitro data showing dose-dependent reduction of PO and LnCap cell viability with GIT-27NO, the i.p. treatment of mice xenografted with either of these cells with GIT-27NO significantly inhibited their growth as compared to the mice-treated with its vehicle. In addition, GIT-27NO given -24 and -1 h prior to e.v. challenge with 20 mg/kg ConA significantly suppressed the increase of transaminases that occurred 8 h after challenge in the control mice that received the vehicle. In addition, relative to these latter groups of mice, the histological signs of inflammatory hepatitis were markedly reduced in ConA-challenged mice that received GIT-27NO. In the hepatitis model, GIT-27NO was equally effective in preventing ConA-induced hepatitis regardless of whether it was administered intra peritoneally or per os. These data confirm that Grr-27NO is a powerful anticancer agent also endowed with pharmacological properties to prevent the development of cell-mediated murine immunoinflammatory hepatitis. (C) 2009 Elsevier B.V. All rights reserved. | en |
dc.description.sponsorship | null | sr |
dc.language.iso | English | sr |
dc.rights | restrictedAccess | |
dc.source | European Journal of Pharmacology | sr |
dc.title | The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Стошић-Грујичић, Станислава Д.; Ницолетти, Фердинандо; Aл-Aбед, Yоусеф; Басиле, Францесцо; Бионди, Aнтонио; Тумино, Салваторе; Мангано, Катиа; Максимовић-Иванић, Данијела Д.; Дониа, Марцо; Мијатовић, Сања A.; Миљковић, Ђорђе М.; | |
dc.citation.issue | 1-3 | sr |
dc.citation.volume | 615 | sr |
dc.citation.epage | 233 | sr |
dc.type.version | publishedVersion | en |
dc.citation.rank | M22 | |
dc.identifier.rcub | https://hdl.handle.net/21.15107/rcub_ibiss_1438 |
Документи
Датотеке | Величина | Формат | Преглед |
---|---|---|---|
Уз овај запис нема датотека. |